ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday

Posted by on Jul 28th, 2026

ImmunityBio (NASDAQ:IBRX – Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $49.1970 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 7, 2026 at 12:30 PM ET.

ImmunityBio (NASDAQ:IBRX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The company had revenue of $44.21 million for the quarter, compared to the consensus estimate of $43.07 million. On average, analysts expect ImmunityBio to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

ImmunityBio Stock Down 0.1%

ImmunityBio stock opened at $6.98 on Tuesday. The company has a market cap of $7.31 billion, a price-to-earnings ratio of -8.12 and a beta of 0.01. The firm’s fifty day moving average is $7.75 and its 200 day moving average is $7.42. ImmunityBio has a 52-week low of $1.95 and a 52-week high of $12.43.

Insiders Place Their Bets

In other news, Director Barry J. Simon sold 25,000 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total value of $197,000.00. Following the sale, the director owned 2,802,788 shares of the company’s stock, valued at approximately $22,085,969.44. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 131,210 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the completion of the sale, the director directly owned 125,386 shares in the company, valued at approximately $1,191,167. This represents a 51.13% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 435,443 shares of company stock valued at $3,918,819 over the last three months. 66.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

A number of large investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. purchased a new stake in ImmunityBio in the 3rd quarter worth about $60,000. Engineers Gate Manager LP boosted its position in shares of ImmunityBio by 15.3% during the fourth quarter. Engineers Gate Manager LP now owns 26,968 shares of the company’s stock valued at $53,000 after buying an additional 3,578 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of ImmunityBio during the fourth quarter valued at approximately $49,000. Janney Montgomery Scott LLC bought a new position in shares of ImmunityBio during the fourth quarter valued at approximately $47,000. Finally, Xponance LLC grew its stake in shares of ImmunityBio by 29.4% during the fourth quarter. Xponance LLC now owns 23,168 shares of the company’s stock valued at $46,000 after buying an additional 5,270 shares during the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on IBRX shares. BTIG Research restated a “buy” rating and issued a $12.00 target price on shares of ImmunityBio in a report on Thursday, May 21st. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of ImmunityBio in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. Finally, D. Boral Capital reissued a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $14.20.

Read Our Latest Stock Report on ImmunityBio

About ImmunityBio

(Get Free Report)

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

Featured Articles

Earnings History for ImmunityBio (NASDAQ:IBRX)

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.